Home › Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA (pembrolizumab) Data
 

Keywords :   


Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA (pembrolizumab) Data

2015-12-08 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. New Findings Presented at 57th American Society of Hematology Annual Meeting in Difficult-to-Treat Blood Cancers Including Multiple Myeloma and Three Types of Lymphoma Broad KEYTRUDA Development Program in Hematology Includes Four Registrational Studies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new study findings investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, across a range of hematological cancers were presented at the 57th American Society of Hematology (ASH) Annual Meeting. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-391-0131orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: add data range growing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Tropical Storm Milton Public Advisory Number 2
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 26
05.10Tropical Storm Milton Graphics
05.10Hurricane Kirk Wind Speed Probabilities Number 26
05.10Hurricane Leslie Graphics
05.10Hurricane Kirk Public Advisory Number 26
05.10Summary for Hurricane Kirk (AT2/AL122024)
More »